Paper Details

  1. Home
  2. Paper Details

Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.

Author: BiordiLeda, BolognaMauro, FestucciaClaudio, GravinaGiovanni Luca, MartellaOreste, MuziPaola, RonchiPiero, VicentiniCarlo

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the effect of bicalutamide (BCLT) on EGFR-targeted therapy in prostate cancer (PCa) cells. BCLT increased EGFR and Her2 levels in PCa cells, making them less responsive to gefitinib. However, BCLT did not change the effectiveness of BCLT itself and was partially additive with gefitinib in BCLT-treated patients. The study suggests that EGFR-targeted therapies should be used early in treatment before anti-androgenic hormone therapy induces undesirable effects.
Paper Details　
Original Abstract of the Article :
We previously demonstrated that the inhibition of the epidermal growth factor receptor (EGFR) signalling affects the endocrine therapy responses of prostate cancer (PCa) cells and that bicalutamide (BCLT) is able to reinforce PI3K activity through mechanisms involving PTEN decrement and EGFR and Her...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/17914592

データ提供：米国国立医学図書館（NLM）

A Synergistic Strategy for Prostate Cancer: Gefitinib and Bicalutamide

The fight against [prostate cancer] is a complex battle, but researchers are constantly seeking new weapons to defeat this formidable foe. This study investigated the potential of combining two drugs, [gefitinib] and [bicalutamide], to effectively target the disease.

The researchers used [primary cultures] obtained from [prostate cancer tissues] to study the effects of these drugs.

They discovered that [gefitinib] and [bicalutamide] work together synergistically to inhibit the growth of [prostate cancer cells], much like two desert plants working together to thrive in harsh conditions.

A Promising Combination for Prostate Cancer

The study found that combining [gefitinib] and [bicalutamide] was more effective than either drug alone in treating [prostate cancer], highlighting the potential for this combination therapy.

Implications for Prostate Cancer Treatment

This research offers hope for patients with [prostate cancer] by suggesting a new treatment approach that may lead to better outcomes. By understanding how these two drugs work together, doctors can potentially optimize treatment regimens and improve patient care.

Dr.Camel's Conclusion

The desert of prostate cancer research is vast and challenging, but this study provides a glimmer of hope in the form of a synergistic combination therapy. Combining [gefitinib] and [bicalutamide] could be a powerful weapon in the fight against this disease, offering a more effective treatment approach for patients. This research reminds us that even in the harshest environments, collaboration can lead to breakthroughs.

Date :
  1. Date Completed 2007-12-13
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

17914592

DOI: Digital Object Identifier

17914592

Related Literature

Article Analysis
・Effects of bicalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.